Invitation & Agenda: Orexo R&D Day on March 24

Orexo AB (Publ.), a Swedish pharmaceutical company, is hosting an R&D Day on March 24, 2026, at the Royal Swedish Academy of Engineering Sciences in Stockholm. This event is designed for investors, analysts, and media, highlighting the company's strategic shifts following the divestment of its Zubsolv® product in the U.S. CEO Nikolaj Sørensen will present Orexo's renewed strategy and research priorities, with particular emphasis on the proprietary drug delivery technology, AmorphOX®.

The agenda includes various presentations from key management figures, including Robert Rönn and Lisa Moore, who will discuss the potential of AmorphOX® in transforming drug delivery methods beyond traditional channels and addressing significant market needs. There will be a special focus on the development of OX640, an intranasal epinephrine product aimed at improving treatment for severe allergy reactions, and OX390, a countermeasure addressing rising threats from synthetic opioids, developed in collaboration with the U.S. BARDA.

Additionally, Dr. Mark A. Smith from Davidson College will provide expert insights on the emerging dangers posed by drug combinations such as xylazine and fentanyl. The day will conclude with a Q&A session, followed by networking opportunities during lunch.

Orexo is committed to advancing therapies for severe diseases and rescue medications, leveraging its innovative AmorphOX® technology to enhance drug formulation and delivery. Attendees can register for the event through Orexo’s dedicated R&D Day webpage. This summit presents an opportunity for stakeholders to gain deeper insights into Orexo's future landscape and growth strategies. For further information, interested parties are encouraged to reach out via Orexo's communication channels.

As the financial landscape continues to evolve, Orexo AB’s upcoming R&D Day on March 24, 2026, presents a vital opportunity for investors and analysts to assess the company’s strategic direction following the divestment of Zubsolv® in the US. The focus on proprietary drug delivery technology, particularly the AmorphOX® platform, signals Orexo's commitment to innovation and market adaptation.

Investors should pay close attention to the management's presentation, particularly the insights from CEO Nikolaj Sørensen regarding strategic priorities aimed at maximizing value creation. With a robust pipeline of products, including OX640 and OX390, Orexo is positioning itself to address significant market needs, specifically in the allergy treatment space and the emerging threats of adulterated substances like xylazine and medetomidine.

The engagement of experts, such as Dr. Mark A. Smith, underscores the importance of addressing public health crises associated with substance abuse. This could resonate well with investors, particularly those interested in companies innovating in the healthcare sector’s most pressing challenges.

Investors should also evaluate Orexo’s ability to capitalize on partnerships and its business development strategies, which will be elaborated on during the event. The emphasis on transitioning from injectable drugs to nasal or tablet delivery methods enhances market potential and scalability of its manufacturing capabilities.

In summary, registering for this event could provide valuable insights into Orexo’s future directions and product pipeline, which may enhance long-term investor confidence. As the company navigates its growth trajectory, those looking to invest in innovative pharmaceuticals might find Orexo a compelling option, particularly given its unique technological offerings and commitment to addressing urgent healthcare needs.